Trial record 1 of 43 for:    Non-Invasive Imaging of Heart Failure
Previous Study | Return to List | Next Study

Noninvasive Imaging of Heart Failure: A Pilot Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT01160471
First received: July 9, 2010
Last updated: April 10, 2014
Last verified: March 2014

July 9, 2010
April 10, 2014
June 2010
Not Provided
Post contrast myocardial T1 measured by CMR.
Not Provided
Complete list of historical versions of study NCT01160471 on ClinicalTrials.gov Archive Site
A) Post contrast myocardial attenuation measured by MDCT. B) LV systolic/diastolic function measured by CMR. C) Serum myocardial extracellular matrix remodelling biomarkers. D) Fibrosis detected by histology analysis in endomyocardial biopsy.
Not Provided
Not Provided
Not Provided
 
Noninvasive Imaging of Heart Failure: A Pilot Study
Noninvasive Imaging of Heart Failure

Background:

- Heart failure is a common cardiovascular disorder whose incidence increases with age, affecting up to 10% of people older than 65 years of age. As the population ages, the prevalence and cost of heart failure will continue to rise. Researchers are interested in using noninvasive imaging methods to better understand the symptoms and effects of heart failure.

Objectives:

- To conduct a noninvasive comparative imaging study of individuals with heart failure.

Eligibility:

- Individuals at least 18 years of age who have been diagnosed with heart failure (with at least mild symptoms and slight limitations on physical activity).

Design:

  • This study will last approximately 2 years and will require four visits to the National Institutes of Health Clinical Center, with one screening visit and three study visits.
  • Participants will be screened with a full medical history and physical examination, as well as blood and urine samples.
  • Participants will have the following tests during each study visit:
  • Physical examination
  • Blood and urine samples
  • Cardiac magnetic resonance imaging
  • Cardiac computerized tomography to study the blood vessels in and leading to the heart
  • Echocardiogram to evaluate heart function
  • Electrocardiogram to measure heart electrical activity
  • The three study visits will take place 1 year apart. Participants will also receive follow-up phone calls 6 months after the first and second visits.
  • No treatment will be provided as part of this protocol.

More than 9% of American men and close to 5% of women ages 60 to 79 years report a diagnosis of heart failure, where above the age of 80 years these figures increase to 13.8% and 12.2%, respectively. Projection into the middle part of this century suggests that, as the population ages, the prevalence and cost of heart failure will continue to rise. The primary aim of this proposal is to investigate noninvasive imaging methods for quantifying diffuse myocardial fibrosis with cardiac magnetic resonance imaging (CMR) in heart failure patients. The secondary aims are to investigate the association between diffuse fibrosis detected by CMR with left ventricular function, and examine the utility of multi-detector CT (MDCT) in detecting diffusion myocardial fibrosis.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Magnetic Resonance Imaging
  • Acquired Heart Disease
  • Myocardial Fibrosis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
196
Not Provided
Not Provided
  • INCLUSION CRITERIA:

The common inclusion criteria between patients and controls are:

A. Able to understand and sign informed consent.

B. Able to complete a MRI or CT scan.

C. Age greater than or equal to 18 years old.

Heart Failure subject:

D. Men and women with a clinical diagnosis of heart failure.

E. New York Heart Association functional class II or worse.

F. For the normal ejection fraction arm.

  1. Preserved left ventricular ejection fraction (EF > 50%)
  2. Diastolic dysfunction defined one or more of the following

    1. LVEDP > 16 mm Hg
    2. PCW > 12 mm Hg
    3. E/E ratio > 15
    4. E/E ratio > 8 AND NT-proBNP > 220 pg/mL

    For the systolic dysfunction arm:

  3. Left ventricular ejection fraction < 40%

    Normal Control:

    G. Men and women without a clinical diagnosis of heart failure.

    H. NIH employees may be involved and NIH requirements will be followed as laid out in NIH Policy Manual 2300-630-3 - Leave Policy For NIH Employees Participating In NIH Medical Research Studies.

    EXCLUSION CRITERIA:

    Individuals will be excluded from the study if they are discovered to have coexistent conditions that may contribute to structural or functional cardiac abnormalities, which may confound interpretation of results, are ineligible for MRI or if they are at increased risk for Nephrogenic Systemic Fibrosis (NSF) including:

    A. Contra indications for gadiolinium-based contrast agent:

    1. eGFR < 30ml/min/1.73m(2)
    2. Acute renal failure, renal transplantation, current dialysis treatment or hepatorenal syndrome
    3. History of liver transplantation or severe liver disease
    4. Severe Asthma
    5. Hemoglobinopathies, sickle cell anemia and thalassemias major
    6. History of multiple myeloma
    7. History of significant allergic reaction to gadolinium-based contrast agents

    B. Coronary artery disease with unstable symptoms or acute coronary syndrome within the last six months.

    C. Medical conditions associated with increased collagen turnover which may confound interpretation of biomarkers of collagen synthesis. Examples include systemic amyloid disease, cirrhosis, liver, pulmonary, or renal fibrosis, inflammatory states, cancer, recent trauma or surgery;

    D. Pregnant or lactating women;

    E. Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial;

    F. Any other conditions that precludes safety for MRI or MDCT per the researcher s evaluation.

    G. Patients otherwise eligible but with any of the following contraindications for iodine-based CT contrast agent will be excluded from contrast CT angiography but may undergo all other study procedures:

    1. Renal dysfunction (defined as eGFR < 45 mL/min/m(2))
    2. Current clinical diagnosis of renal failure
    3. Prior hypersensitivity to iodine containing substances (shellfish, iodine, and or previous contrast reactions to contrast agents.
Both
18 Years and older
No
Contact: Marissa B Mallek (301) 496-7700 marissa.mallek@nih.gov
Contact: David A Bluemke, M.D. (301) 402-1854 bluemked@mail.nih.gov
United States
 
NCT01160471
100153, 10-CC-0153
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC)
Not Provided
Principal Investigator: David A Bluemke, M.D. National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP